Title: Clinical observation on the effects of low dosage imatinib to chronic myelogenous leukemia in blast crisis
Abstract: OBJECTIVE To observe the efficacy and safety of low dosage imatinib in the treatment of chronic myelogenous leukemia in the blast crisis (CML-BC). METHODS 8 patients with CML-BC who had received interferon and hydroxyurea were treated with 200-300 mg·d -1 of oral imatinib for 18 to 94 weeks. RESULS 4 patients achieved complete hematological response and 2 patients achieved major hematological response.Imatinib induced major cytogenetic response in 2 patients and improved cytogenetic response in 2 patients. The adverse effects were little and tolerable. CONCLUSION Low dosage imatinib has also improved hematologic and cytogenetic responses in patients with CML-BC who had failed in previous therapy of interferon and hydroxyurea. Further investigation is required for long_term effects of low dosage imatinib on CML-BC.
Publication Year: 2004
Publication Date: 2004-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot